UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035530
Receipt number R000040480
Scientific Title Risk stratification in Brugada syndrome: analysis of unipolar Holter electrocardiogram after Pilsicainide provocation.
Date of disclosure of the study information 2019/01/12
Last modified on 2019/01/12 15:16:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Risk stratification in Brugada syndrome: analysis of unipolar Holter electrocardiogram after Pilsicainide provocation.

Acronym

Unipolar Holter electrocardiogram after Pilsicainide provocation in Brugada syndrome.

Scientific Title

Risk stratification in Brugada syndrome: analysis of unipolar Holter electrocardiogram after Pilsicainide provocation.

Scientific Title:Acronym

Unipolar Holter electrocardiogram after Pilsicainide provocation in Brugada syndrome.

Region

Japan


Condition

Condition

Brugada syndrome

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the prognostic value for fatal ventricular arrhythmias using unipolar Holter ECG (Fukuda Electronics Co., Ltd.: FM - 980) after pilsicainide provocation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To evaluate late potentials [LP: filtered QRS(f-QRS), duration of low-amplitude signals :LAS40 and root mean square voltage:RMS40], ST amplitude(mV), QTc interval, J amplitude and T-wave alternans (TWA) in leads V2 and V5 on unipolar Holter electrocardiogram after the plisicainide provocation.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Consecutive patients who with Brugada syndrome

Key exclusion criteria

1) Patients with bundle branch block.
2)Patients with left ventricular dysfunction and/or structural heart diseases.
3) Patients who have an invasive therapy for other disease.
4) Patients who cannot undergo Holter ECG.
5) Patients who rejected the inclusion in this study.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masahiko Takagi

Organization

Kansai Medical University

Division name

Department of Medicine 2

Zip code


Address

10-15 Fumizono-cho, Moriguchi, Osaka

TEL

(06)6992-1001

Email

takagims@takii.kmu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Masahiko Takagi

Organization

Kansai Medical University

Division name

Department of Medicine 2

Zip code


Address

10-15 Fumizono-cho, Moriguchi, Osaka

TEL

(06)6992-1001

Homepage URL


Email

takagims@takii.kmu.ac.jp


Sponsor or person

Institute

Department of Medicine 2 Kansai Medical University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

関西医科大学総合医療センター(大阪府)/ Kansai Medical University Medical Center


Other administrative information

Date of disclosure of the study information

2019 Year 01 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2018 Year 10 Month 02 Day

Date of IRB


Anticipated trial start date

2018 Year 10 Month 02 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective study.
We'll enroll the patients with Brugada-type ECG from IRB approval to Mar. 2023.
We'll perform unipolar Holter ECG after Pilsicainide provocation and identify the prognostic risk factors by evaluating late potentials, ST amplitue, dQTc interva, J wave amplitude and T-wave alternans (TWA).


Management information

Registered date

2019 Year 01 Month 12 Day

Last modified on

2019 Year 01 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040480


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name